Feature|Videos|December 10, 2024
Breaking barriers: EnzeneX™ to EnzeneX™ 2.0
Author(s)Enzene
Shilpa Gadgil, PhD (VP, Head of Process and Analytical Development, Head of CDMO Development) discusses Enzene's new technologies and the New Jersey site capabilities.
Shilpa Gadgil, PhD, from Enzene, discusses the company's Fully-Connected Continuous Manufacturing™ (FCCM™) platform and EnzeneX™ 2.0 for commercial biologics supply, as well as which large molecules have been successfully produced using the platforms. She also covers Enzene's new biologics site in New Jersey and the bottlenecks the company has overcome regarding transfer and scale-up.
Related Content
Trending on Pharmaceutical Technology
1
Shilpa CDMO to Launch as Dedicated Complex Small-Molecule Contract Development and Manufacturing Brand at CPHI Milan
2
Technology Transfer: Success Drivers and Obstacles Explained
3
Assessment of Silicone Oil Cleaning on Indirect Surfaces in Aseptic Manufacturing
4
European Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalized
5